Photo from Joshua Brody/X
Aug 9, 2024, 10:21
Immunotherapy with chemo improves survival for aggressive relapsed lymphoma
Joshua Brody, Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“In relapsed aggressive lymphoma, adding bispecific CD3xCD20 immunotherapy to chemo DOUBLES Overall Survival and Complete Remissions! To 59%!
STARGLO trial treating patients at ~70 hospitals around the world including Mount Sinai.”
Read further.
Source: Joshua Brody/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14